Brennan Aoife
Transaction: 06/11/2026
BUY
Change
+5,000
Price
$7.99
Filing
06/12/2026
Type
BUY
Xilio Therapeutics, Inc.
XLO • Biotechnology
$9.00
▼ -0.02 (-0.22%)
Current price
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$1.75B
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.2Healthy liquidity · 2.58Negative growth trendWeak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:29 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$9.00
Change-0.22%
Shares Out194.05M
Market Cap$1.75B
Enterprise Value$1.62B
52W Range6.47 - 12.74
Beta-0.12
P/E-112.99
P/S27.25
P/B24.17
P/FCF-28.50
EV/Sales25.22
Price$9.00
Change-0.22%
Shares Out194.05M
Market Cap$1.75B
Enterprise Value$1.62B
52W Range6.47 - 12.74
Beta-0.12
P/E-112.99
P/S27.25
P/B24.17
P/FCF-28.50
EV/Sales25.22
EV/EBITDA-53.25
EV/FCF-26.39
Earnings Yield-0.89%
FCF Yield-3.51%
Dividend Yield0.00%
Gross Margin96.48%
Oper. Margin-95.92%
Profit Margin-80.05%
Debt/Eq0.20
Current Ratio2.58
Quick Ratio2.58
Target$98.00
Target Upside988.89%
Target Median$98.00
Target Range98.00 - 98.00
Volume13.27K
Avg Volume43.68K
EPS Surprise0.08
Investment DNA
How strong this company looks for long-term investors
29
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
20/100
Why this score▼
Manageable debt level · 0.2Healthy liquidity · 2.58Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 3 analyst votes · 2026-09-05
100/100
Bullish
Bullish
3
Hold
0
Bearish
0
Price Target
2026-08-14
Low
$98.00
Mean
$98.00
Median
$98.00
High
$98.00
Insider Transactions
Recent executive and insider activity
Bonstein Sara
Transaction: 06/11/2026
BUY
Change
+5,000
Price
$7.99
Filing
06/12/2026
Type
BUY
ROSS ROBERT W.
Transaction: 06/11/2026
BUY
Change
+5,000
Price
$7.99
Filing
06/12/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Brennan Aoife | BUY | +5,000 | $7.99 | 06/11/2026 | 06/12/2026 |
| Bonstein Sara | BUY | +5,000 | $7.99 | 06/11/2026 | 06/12/2026 |
| ROSS ROBERT W. | BUY | +5,000 | $7.99 | 06/11/2026 | 06/12/2026 |
| Xu Yuan | BUY | +5,000 | $7.99 | 06/11/2026 | 06/12/2026 |
| Curran Daniel J. | BUY | +5,000 | $7.99 | 06/11/2026 | 06/12/2026 |
| Shannon James Samuel | BUY | +5,000 | $7.99 | 06/11/2026 | 06/12/2026 |
| Bello Akintunde Olatokumbo | BUY | +5,000 | $7.99 | 06/11/2026 | 06/12/2026 |
| Blanchard Cheryl R | OTHER | 0 | Not reported | 04/15/2026 | 04/16/2026 |
| Blanchard Cheryl R | BUY | +10,000 | $8.40 | 04/15/2026 | 04/16/2026 |
| Shannon James Samuel | BUY | +5,000 | $8.79 | 03/26/2026 | 03/30/2026 |
| GILEAD SCIENCES, INC. | BUY | +3,739,000 | $0.00 | 02/13/2026 | 02/17/2026 |
| Frankenfield Christopher James | SELL | -7,030 | $0.64 | 01/02/2026 | 01/05/2026 |
| Brennan Kevin M. | SELL | -1,826 | $0.64 | 01/02/2026 | 01/05/2026 |
| Russo Rene | SELL | -44,250 | Not reported | 01/01/2026 | 01/05/2026 |
| Russo Rene | BUY | +44,250 | Not reported | 01/01/2026 | 01/05/2026 |
| Frankenfield Christopher James | BUY | +19,375 | Not reported | 01/01/2026 | 01/05/2026 |
| Frankenfield Christopher James | SELL | -19,375 | Not reported | 01/01/2026 | 01/05/2026 |
| Brennan Kevin M. | BUY | +5,000 | Not reported | 01/01/2026 | 01/05/2026 |
| Brennan Kevin M. | SELL | -5,000 | Not reported | 01/01/2026 | 01/05/2026 |
| Luptakova Katarina | BUY | +16,625 | Not reported | 01/01/2026 | 01/05/2026 |